NASDAQ$MRVI
Maravai LifeSciences Holdings Inc. · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Reported a revenue increase driven by higher demand for GMP CleanCap analogs, GMP mRNA, and Glen Research product portfolio, but partially offset by decreased biologics safety testing revenue due to lower demand trends in China, with net loss and Adjusted EBITDA decreasing compared to the same period last year.
Maravai LifeSciences reported a 6.5% increase in revenue to $73.4 million for Q2 2024, driven by growth in Nucleic Acid Production. However, the company experienced a net loss of $(14.5) million and an Adjusted EBITDA of $16.9 million, both lower than the previous year. They reaffirmed their full-year revenue guidance of $265.0 million to $285.0 million.
- Revenue for the second quarter was $73.4 million, a 6.5% increase year-over-year.
- Nucleic Acid Production revenue increased by 9.8% to $58.5 million, driven by higher demand for GMP CleanCap analogs, GMP mRNA, and Glen Research products.
- Biologics Safety Testing revenue decreased by 4.7% to $14.9 million due to lower demand trends in China.
- Net loss was $(14.5) million and Adjusted EBITDA was $16.9 million for the quarter.
Headline financials
Revenue & EPS history
Maravai · Revenue · Quarterly
$71.9M
Revenue by segment
Maravai · $66.9M total across 2 segments · Q3 2023
- TriLink$51.2M-70.7%76.6%
- Cygnus$15.6M-4.5%23.4%
Forward guidance
Maravai reaffirmed its revenue guidance for the full year 2024 in the range of $265.0 million to $285.0 million and expects Adjusted EBITDA margins to be in the range of 20% to 22%.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
-0.2%
Avg return
Earnings day
+2.1%
Avg return
5 days after
+1.1%
Avg return
30 days after
42%
10 / 24 earnings
Positive
+58.9%
Q4 2023
Best reaction
-36.7%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +23.4% | +10.9% | +27.5% | |
| Q4 2025 | +9.9% | +13.2% | -12.3% | |
| Q3 2025 | -0.7% | +12.5% | +28.0% | |
| Q1 2025 | -2.4% | -0.9% | +6.6% | |
| Q4 2024 | -6.4% | -13.2% | -31.4% | |
| Q3 2024 | -36.7% | -29.0% | -37.1% | |
| Q2 2024 | -6.7% | -4.3% | -0.4% | |
| Q1 2024 | +10.0% | +17.5% | -3.9% | |
| Q4 2023 | +58.9% | +57.0% | +66.5% | |
| Q3 2023 | -31.3% | -25.0% | -24.3% | |
| Q2 2023 | -3.5% | -10.1% | -5.7% | |
| Q1 2023 | -16.4% | +2.5% | -3.3% | |
| Q4 2022 | +6.9% | +3.2% | -2.4% | |
| Q3 2022 | -11.7% | -13.8% | -15.3% | |
| Q2 2022 | +2.2% | -3.5% | -20.7% | |
| Q1 2022 | +6.1% | -2.9% | +6.7% | |
| Q4 2019 | +1.4% | +1.1% | -9.7% | |
| Q4 2021 | -1.6% | +14.8% | +7.0% | |
| Q3 2020 | -1.7% | -0.4% | +6.3% | |
| Q3 2021 | +1.6% | +3.1% | +10.1% | |
| Q2 2021 | -5.7% | +8.8% | +0.6% | |
| Q1 2020 | +4.0% | +8.6% | +26.5% | |
| Q1 2021 | -4.8% | +2.1% | +13.1% | |
| Q4 2020 | -0.4% | -2.4% | -6.3% | |
| Q2 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro